home / stock / annx / annx quote
Last: | $4.795 |
---|---|
Change Percent: | 0.0% |
Open: | $4.66 |
Close: | $4.795 |
High: | $4.91 |
Low: | $4.62 |
Volume: | 922,623 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.795 | $4.66 | $4.795 | $4.91 | $4.62 | 922,623 | 07-04-2024 |
$4.795 | $4.66 | $4.795 | $4.91 | $4.62 | 922,623 | 07-03-2024 |
$4.565 | $4.98 | $4.565 | $5.09 | $4.52 | 1,395,892 | 07-02-2024 |
$5.05 | $4.98 | $5.05 | $5.15 | $4.82 | 2,558,539 | 07-01-2024 |
$4.9 | $4.83 | $4.9 | $4.99 | $4.67 | 5,289,932 | 06-28-2024 |
$4.82 | $4.62 | $4.82 | $5.1 | $4.5 | 2,568,044 | 06-27-2024 |
$4.65 | $4.75 | $4.65 | $4.79 | $4.45 | 3,983,868 | 06-26-2024 |
$4.58 | $4.78 | $4.58 | $4.83 | $4.52 | 1,544,995 | 06-25-2024 |
$4.77 | $5 | $4.77 | $5.05 | $4.745 | 1,465,938 | 06-24-2024 |
$4.98 | $5.25 | $4.98 | $5.3 | $4.93 | 2,550,464 | 06-21-2024 |
$5.2 | $5.04 | $5.2 | $5.22 | $4.98 | 2,030,419 | 06-20-2024 |
$5.07 | $5.32 | $5.07 | $5.36 | $5.03 | 1,833,583 | 06-19-2024 |
$5.07 | $5.32 | $5.07 | $5.36 | $5.03 | 1,833,583 | 06-18-2024 |
$5.36 | $5.59 | $5.36 | $5.62 | $5.33 | 1,096,383 | 06-17-2024 |
$5.62 | $5.89 | $5.62 | $5.98 | $5.61 | 1,441,384 | 06-14-2024 |
$6.01 | $5.96 | $6.01 | $6.22 | $5.84 | 1,267,826 | 06-13-2024 |
$6.04 | $5.6 | $6.04 | $6.4799 | $5.5601 | 2,437,982 | 06-12-2024 |
$5.46 | $5.66 | $5.46 | $5.7 | $5.23 | 3,052,843 | 06-11-2024 |
$5.72 | $5.7 | $5.72 | $5.84 | $5.56 | 2,136,392 | 06-10-2024 |
$5.74 | $5.78 | $5.74 | $5.82 | $5.32 | 4,623,736 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...
2024-06-17 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...